Does Presbyterian Healthcare Services Cover Cialis?

What Presbyterian Healthcare Services Is and How Its Formulary Works

Presbyterian Healthcare Services is an integrated health system and insurer based in Albuquerque, New Mexico. The organization operates Presbyterian Health Plan, a nonprofit health maintenance organization serving commercial, Medicaid (Centennial Care), and Medicare members across New Mexico. Each plan type maintains its own formulary, which is the list of covered drugs organized into tiers that determine your copay or coinsurance.

Formulary decisions at Presbyterian Health Plan are made by a Pharmacy and Therapeutics (P&T) committee that reviews clinical evidence, FDA approvals, and cost data on a quarterly basis. Drugs placed on lower tiers cost members less at the pharmacy. Understanding which tier tadalafil occupies on your specific plan determines whether Cialis or its generic is affordable with your coverage.

How Drug Tiers Affect Your Copay

Most Presbyterian Health Plan formularies use a four-to-five-tier structure. Generic drugs typically sit at Tier 1 or Tier 2, preferred brand-name drugs at Tier 3, and non-preferred brands at Tier 4. Specialty drugs occupy Tier 5. Generic tadalafil, when covered, usually falls at Tier 2 with copays in the $10, $50 range per 30-day supply. Brand-name Cialis, if listed at all, typically occupies Tier 3 or Tier 4, raising costs to $60, $150 or more per fill depending on plan design.

Medicaid vs. Commercial vs. Medicare Coverage Rules

Coverage rules differ substantially across plan types. Presbyterian's Centennial Care Medicaid plan follows New Mexico Human Services Department drug policy, which may exclude or restrict erectile dysfunction drugs. Medicare Part D plans that Presbyterian administers must comply with CMS formulary requirements. CMS does not require Part D plans to cover drugs used exclusively for sexual dysfunction, meaning tadalafil for ED alone may not be covered under Medicare. Tadalafil prescribed for BPH (benign prostatic hyperplasia), however, carries a separate indication and may be covered under Medicare Part D. The FDA approved tadalafil 5 mg daily specifically for BPH in 2011 [1].

Does Cialis (Tadalafil) Have FDA Approval for the Indication Being Treated?

Tadalafil received FDA approval for erectile dysfunction in 2003 under the brand name Cialis. The FDA also approved it for pulmonary arterial hypertension (as Adcirca, 40 mg daily) and for BPH. Understanding which indication appears on the prescription matters because insurers, including Presbyterian Health Plan, may cover tadalafil for BPH or pulmonary hypertension while denying claims written solely for erectile dysfunction.

The FDA label for tadalafil 5 mg daily states that the drug is indicated for the treatment of erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia [1]. A single prescription for a patient with both ED and BPH may therefore qualify for coverage under the BPH indication even if the ED indication alone would be denied.

Clinical Evidence Supporting Tadalafil

Tadalafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class. The key registration trial published in the European Urology journal showed that tadalafil 20 mg on-demand improved the International Index of Erectile Function (IIEF) erectile function domain score by 7.6 points over placebo (P<0.001) in men with mild-to-severe ED [2]. A 2014 Cochrane systematic review (25 trials, N=14,597) concluded that PDE5 inhibitors produce meaningful improvements in IIEF scores and successful intercourse rates compared with placebo [3].

For BPH, the PATENT-1 trial and subsequent pooled analyses demonstrated that tadalafil 5 mg daily reduced International Prostate Symptom Score (IPSS) by 5.6 points versus 3.6 points for placebo after 12 weeks (P<0.001) [4]. This BPH evidence base strengthens the case for formulary coverage when that diagnosis is documented.

PDE5 Inhibitors in Cardiovascular Context

Prescribers and insurers pay close attention to cardiovascular safety before approving PDE5 inhibitors. The Princeton Consensus III guidelines, endorsed by the American Heart Association, stratify men with ED into low, intermediate, and high cardiovascular risk categories before recommending treatment [5]. Men in the low-risk category (controlled hypertension, fewer than three major coronary artery disease risk factors) can safely initiate PDE5 inhibitor therapy without additional cardiac evaluation. This risk stratification may appear in prior authorization criteria for Presbyterian Health Plan.

How to Check Your Presbyterian Health Plan Formulary for Tadalafil

The fastest verification method is the online formulary tool on the Presbyterian Health Plan member portal at phs.org. Enter "tadalafil" or "Cialis" in the drug search box, then select your plan year and plan name from the dropdown.

If the portal is unavailable or unclear, call the member services number printed on the back of your insurance card. Ask the representative three specific questions: Is tadalafil (generic) covered on my plan? Is brand-name Cialis covered? Does my plan require prior authorization or a quantity limit for tadalafil?

Prior Authorization Requirements

Prior authorization (PA) for tadalafil commonly requires the prescribing physician to document the patient's erectile dysfunction diagnosis using ICD-10 code N52.9 (male erectile dysfunction, unspecified) or a more specific code such as N52.01 (erectile dysfunction due to arterial insufficiency). Presbyterian Health Plan's PA forms typically ask for the patient's failed trial of lifestyle modification, any contraindications to specific dosing, and cardiovascular risk status.

If your physician submits a PA request and it is denied, you have the right to a formal appeal. Federal law under the Employee Retirement Income Security Act (ERISA) guarantees appeal rights for employer-sponsored plans [6]. New Mexico state insurance regulations also protect individual and small-group market members with appeal timelines that insurers must meet.

Quantity Limits on Tadalafil

Even when covered, Presbyterian Health Plan (like most insurers) may impose quantity limits. A common restriction is six tablets per 30 days for on-demand tadalafil 10 mg or 20 mg. Daily-dose tadalafil 2.5 mg or 5 mg may be limited to a 30-day supply per fill. Requests for quantities above those limits require a separate medical exception from the prescribing provider with documentation of medical necessity.

Generic Tadalafil vs. Brand-Name Cialis: Coverage and Cost Differences

Generic tadalafil became available in the United States in 2018 after Eli Lilly's patent exclusivity expired. The FDA requires generic manufacturers to demonstrate bioequivalence to the brand, meaning the generic delivers the same amount of active drug to the bloodstream within the same time window as Cialis [7]. From a clinical standpoint, there is no meaningful efficacy difference between brand and generic.

From a coverage standpoint, the difference is significant. Brand-name Cialis carries a wholesale acquisition cost exceeding $400 for a 30-day supply of 20 mg tablets. Generic tadalafil from multiple manufacturers now has a retail cash price of $25, $80 per 30-day supply depending on the pharmacy and tablet strength. Presbyterian Health Plan's P&T committee is likely to classify brand-name Cialis as non-preferred or exclude it from the formulary entirely, while covering generic tadalafil at a lower tier.

Therapeutic Substitution Policies

Some Presbyterian Health Plan pharmacy benefit structures allow pharmacists to substitute a covered generic when a prescriber writes for a brand-name drug. If your physician writes "Cialis," the pharmacist may dispense tadalafil with a simple generic substitution without requiring a new prescription in most states, including New Mexico under state pharmacy law. Ask your pharmacist specifically about this substitution at the point of dispensing.

Prior Authorization: Step-by-Step Process for Presbyterian Health Plan Members

Securing prior authorization for tadalafil under Presbyterian Health Plan follows a defined workflow that typically takes 3 to 15 business days from submission to decision.

Step 1: Physician Documents the Diagnosis

Your provider records an appropriate ICD-10 diagnosis code in the electronic health record (N52.9 for erectile dysfunction, N40.1 for BPH with lower urinary tract symptoms). The diagnosis must align with the drug being prescribed. A mismatch between diagnosis and drug on the PA form is the most common reason for automatic denials.

Step 2: Provider Submits the PA Request

The prescribing physician or their office staff submits the PA form to Presbyterian Health Plan's pharmacy benefit management (PBM) partner. Presbyterian Health Plan uses an integrated PBM, so the form goes directly to the plan. Electronic prior authorization (ePA) through the prescriber's EHR system is the fastest route.

Step 3: Plan Review and Decision

The plan's pharmacy team reviews the submission against clinical coverage criteria. The American Urological Association (AUA) guideline on erectile dysfunction recommends PDE5 inhibitors as first-line therapy for most men with ED, which supports medical necessity arguments during this review [8]. If additional information is needed, the plan contacts the prescriber's office.

Step 4: Member Notification

Presbyterian Health Plan notifies both the member and the prescriber of the decision. An approval comes with an authorization number and a duration (often 12 months) after which re-authorization is needed.

Step 5: Appeal if Denied

A denial triggers your right to a first-level internal appeal. Submit the appeal in writing within the timeframe specified in the denial letter (usually 60 to 180 days depending on plan type). Include supporting clinical documentation such as the AUA ED guideline citation [8], lab results confirming hypogonadism or vascular ED if applicable, and a letter from your physician explaining why tadalafil is medically necessary.

What to Do If Presbyterian Health Plan Denies Coverage

A coverage denial does not end your options. Several pathways exist that may reduce or eliminate your out-of-pocket cost for tadalafil.

Manufacturer Patient Assistance

Eli Lilly operates the Lilly Cares Foundation patient assistance program for brand-name Cialis for eligible patients who meet income criteria [9]. Income thresholds and application requirements change annually; visit the Lilly Cares website or call 1-800-545-5979 for current eligibility rules.

Pharmacy Discount Programs

GoodRx and similar discount programs negotiate cash prices for generic tadalafil at major pharmacy chains. As of 2025, GoodRx coupons reduce the cash price of generic tadalafil 20 mg (six tablets) to approximately $15, $35 at CVS, Walgreens, and Walmart pharmacies. These prices are often lower than the insurance copay for Tier 3 or Tier 4 drugs, making them worth comparing even when coverage exists.

Telehealth Prescribing Platforms

HealthRX and similar telehealth platforms offer subscriptions that include tadalafil at significantly reduced cash prices, often $1, $3 per tablet for generic tadalafil, shipped directly to the member. This route bypasses the insurance formulary entirely and is appropriate when the cost of navigating prior authorization exceeds the financial benefit of coverage.

Switching to a Covered PDE5 Inhibitor

If tadalafil is not covered but another PDE5 inhibitor is, your physician may prescribe sildenafil (generic Viagra) instead. Sildenafil is the most widely covered PDE5 inhibitor on commercial formularies given its long generic availability and low cost. A 2018 meta-analysis in the Journal of Sexual Medicine (N=82 trials, N=33,815 participants) found that sildenafil, tadalafil, vardenafil, and avanafil produced similar rates of successful intercourse, with tadalafil showing a modest preference among patients for its longer duration of action (up to 36 hours vs. 4 to 6 hours for sildenafil) [10]. If a formulary-covered alternative exists, a therapeutic substitution may solve the access problem without an appeal.

Erectile Dysfunction: Prevalence, Diagnosis Standards, and Why Coverage Matters

Erectile dysfunction affects an estimated 30 million men in the United States according to data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [11]. Prevalence rises sharply with age: the Massachusetts Male Aging Study found ED rates of approximately 40% in men aged 40 years, increasing to nearly 70% in men aged 70 years [12]. ED is also a recognized marker of cardiovascular disease. Men with ED have a roughly 44% higher risk of a major cardiovascular event compared with men without ED, based on a meta-analysis published in JAMA Internal Medicine (25 prospective studies, N=154,794) [13].

Given this cardiovascular association, treating ED is not strictly cosmetic. The American College of Cardiology and American Heart Association recognize ED as an independent predictor of cardiovascular risk in men [5]. This clinical context supports arguments for medical necessity during insurance appeals.

Diagnosis Criteria That Support a Covered Claim

Presbyterian Health Plan's clinical coverage criteria for tadalafil are not publicly posted in full detail, but most commercial insurers align coverage criteria with recognized diagnostic standards. The AUA recommends that ED diagnosis be based on a validated questionnaire such as the IIEF-5 (Sexual Health Inventory for Men) with a score of 21 or below indicating some degree of ED [8]. A documented IIEF-5 score in the chart, combined with the ICD-10 code, strengthens the prior authorization submission and the appeals record.

Laboratory evaluation supporting organic ED (low serum testosterone, elevated fasting glucose, lipid abnormalities) further documents medical necessity. The Endocrine Society guideline recommends measuring morning total testosterone in men with ED and symptoms of androgen deficiency [14]. A confirmed low testosterone level (below 300 ng/dL by most laboratory reference ranges) establishes a comorbid condition that supports comprehensive treatment planning including PDE5 inhibitor therapy.

Testosterone and PDE5 Inhibitor Combination in Hypogonadal Men

Men with hypogonadism and ED may respond suboptimally to PDE5 inhibitors alone. A randomized controlled trial published in the Journal of Urology (N=140) found that testosterone replacement therapy combined with sildenafil produced greater improvement in IIEF scores than sildenafil alone in hypogonadal men with ED (mean IIEF improvement 8.4 vs. 5.9 points, P<0.05) [15]. For Presbyterian Health Plan members with documented hypogonadism, a comprehensive treatment plan including testosterone replacement may support the medical necessity argument for tadalafil as an adjunct therapy, potentially improving coverage outcomes.

Medicare and Medicaid Coverage of Tadalafil Through Presbyterian Health Plan

Presbyterian Health Plan administers Medicare Advantage plans in New Mexico under the name Presbyterian MediCare PPO and HMO options. CMS regulations specify that Medicare Part D plans are not required to cover drugs when used solely for erectile dysfunction, cosmetic purposes, or symptomatic relief of a non-covered indication. This means tadalafil prescribed specifically for ED may not be covered under any Presbyterian Medicare plan.

Tadalafil prescribed for BPH is not excluded under Medicare Part D because BPH is not on the excluded indications list. Men with documented BPH and co-existing ED may obtain tadalafil 5 mg daily under the BPH indication through a Medicare Part D plan. The prescriber should explicitly note the BPH indication (ICD-10 N40.1) as the primary diagnosis on the prescription.

For Medicaid through Presbyterian Centennial Care, New Mexico's Medicaid formulary is governed by the Human Services Department Preferred Drug List. Erectile dysfunction drugs have historically been excluded from most state Medicaid programs. Tadalafil for pulmonary arterial hypertension (at 40 mg daily dosing, branded as Adcirca) follows entirely different coverage rules and is typically covered as a specialty drug [16].

Questions to Ask Your Doctor and Your Insurance Plan

Navigating tadalafil coverage requires clear communication with both your physician and your insurer. Bring these specific questions to your next appointment and your next call to Presbyterian Health Plan member services.

Ask your physician: Can you document both the ED diagnosis and the BPH diagnosis if both are present? Which ICD-10 code will appear as the primary diagnosis on the prescription? Will your office submit the prior authorization request, or do I need to initiate it? If tadalafil is denied, will you consider prescribing sildenafil as a covered alternative?

Ask Presbyterian Health Plan: Is tadalafil (NDC for the generic or brand-name Cialis) on my formulary for the current plan year? What tier is it on, and what is my copay? Is prior authorization required, and what clinical criteria must be met? What is the quantity limit per 30-day fill? If denied, what is the appeals deadline and process?

Getting these answers in writing (via the insurer's secure member portal messaging system) creates a record that may be useful during appeals.

The AUA guideline on ED states directly: "Phosphodiesterase type 5 inhibitors are the first-line therapy for erectile dysfunction in the appropriately selected patient" [8]. Citing this in an appeal letter positions the request within the recognized standard of care, making denial harder to sustain on clinical grounds.